타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Anti-CD19 Antibody-Drug Conjugate (Loncastuximab Tesirine, Loncastuximab Tesirine (Anti-CD19 Antibody-Drug Conjugate)) ADC Therapeutics·CD19 48 trials |
|---|---|
Overview Program | Loncastuximab Tesirine (Anti-CD19 Antibody-Drug Conjugate) |
Overview Company | ADC Therapeutics |
Overview Modality | ADC |
Overview Target | CD19 |
Overview Indication | Diffuse Large B-Cell Lymphoma; High-grade B-cell Lymphoma (HGBCL) |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Editorial scope · structured catalog |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Linker | linker, or payload that have limited their development |
MoA Mechanism | targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen |
MoA Biomarker | CD19-positive |
Toxicology Species | Cynomolgus monkey |
Toxicology Animal (cat.) | NHP |
Toxicology Major finding | Hepatotoxicity, Including Drug-Induced Liver Injury : Monitor liver function tests during t |
Clinical Safety signal | Hepatotoxicity, Including Drug-Induced Liver Injury : Monitor liver function tests during t |
Clinical Program phase | PHASE_2 |
Clinical Trial activity | No active/completed counts |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Anti-CD19 Antibody-Drug Conjugate (Loncastuximab Tesirine, Loncastuximab Tesirine (Anti-CD19 Antibody-Drug Conjugate)) ADC Therapeutics·CD19 48 trials |
|---|---|
Overview Program | Loncastuximab Tesirine (Anti-CD19 Antibody-Drug Conjugate) |
Overview Company | ADC Therapeutics |
Overview Modality | ADC |
Overview Target | CD19 |
Overview Indication | Diffuse Large B-Cell Lymphoma; High-grade B-cell Lymphoma (HGBCL) |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Editorial scope · structured catalog |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Linker | linker, or payload that have limited their development |
MoA Mechanism | targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen |
MoA Biomarker | CD19-positive |
Toxicology Species | Cynomolgus monkey |
Toxicology Animal (cat.) | NHP |
Toxicology Major finding | Hepatotoxicity, Including Drug-Induced Liver Injury : Monitor liver function tests during t |
Clinical Safety signal | Hepatotoxicity, Including Drug-Induced Liver Injury : Monitor liver function tests during t |
Clinical Program phase | PHASE_2 |
Clinical Trial activity | No active/completed counts |
추천 비교
추천 비교